{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:57:38Z","timestamp":1774526258487,"version":"3.50.1"},"reference-count":22,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"unspecified","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,9,27]]},"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To examine factors associated with accrual rate in industry sponsored clinical trials supporting US Food and Drug Administration (FDA) cancer drug approvals from 2015 to 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting and participants<\/jats:title>\n                    <jats:p>Retrospective cross-sectional study included 194 pivotal trials supporting cancer drug approvals by the US FDA from 2015 to 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Clinical trials were analysed for the type of blinding, primary endpoint, whether crossover was specified in the publication, study phase, line of therapy, response rate, investigational sites, manufacturer and randomisation ratio.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>The main outcome was the rate of accrual, which is the number of patients accrued in the study per open month of enrolment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study consisted of 133 randomised (68%) and 61 (32%) non-randomised clinical trials. In randomised studies, we found the accrual rate was higher in trials investigating first and second line drugs (adjusted rate ratios (aRR): 1.55, 95%\u2009CI 1.18 to 2.09), phase III trials (aRR: 2.13, 95%\u2009CI 1.48 to 2.99), and for studies sponsored by Merck (aRR: 1.47, 95%\u2009CI 1.18 to 2.37), adjusting for other covariates. In contrast, the primary endpoint of a study, presence of crossover, single agent response rate, the number of investigational sites, population disease burden and skewed randomisation ratios were not associated with the rate of accrual. In the non-randomised adjusted model, the accrual rate was 2.03 higher (95%\u2009CI 1.10 to 3.92) for clinical trials sponsored by manufacturer, specifically Merck. Primary endpoint, crossover, trial phase, response rate, the number of investigational sites, disease burden or line of therapy were not associated with the rate of accrual.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this cross-sectional study, line of therapy, study phase and manufacturer were the only factors associated with accrual rate. These findings suggest many proffered factors for speedy trial accrual are not associated with greater enrolment rates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-064458","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T12:14:19Z","timestamp":1665144859000},"page":"e064458","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015\u20132020)"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3635-5212","authenticated-orcid":false,"given":"Kristina","family":"Jenei","sequence":"first","affiliation":[{"name":"School of Population and Public Health, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7876-3978","authenticated-orcid":false,"given":"Alyson","family":"Haslam","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timoth\u00e9e","family":"Olivier","sequence":"additional","affiliation":[{"name":"Department of Oncology, Geneva University Hospital, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milos","family":"Miljkov\u00edc","sequence":"additional","affiliation":[{"name":"Cartesian Therapeutics, Gaithersburg, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"key":"2025121407011732000_12.10.e064458.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.22.2720"},{"key":"2025121407011732000_12.10.e064458.2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/jnci\/djy221","article-title":"Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation","volume":"111","author":"Unger","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2025121407011732000_12.10.e064458.3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jnci\/dju229","article-title":"Adult cancer clinical trials that fail to complete: an epidemic?","volume":"106","author":"Stensland","year":"2014","journal-title":"JNCI J Natl Cancer Inst"},{"key":"2025121407011732000_12.10.e064458.4","doi-asserted-by":"publisher","DOI":"10.1177\/1740774514558307"},{"key":"2025121407011732000_12.10.e064458.5","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0003"},{"key":"2025121407011732000_12.10.e064458.6","doi-asserted-by":"crossref","first-page":"100843","DOI":"10.1016\/j.conctc.2021.100843","article-title":"Trial-level factors affecting accrual and completion of oncology clinical trials: a systematic review","volume":"24","author":"Hauck","year":"2021","journal-title":"Contemp Clin Trials Commun"},{"key":"2025121407011732000_12.10.e064458.7","unstructured":"Allen J , Bergman K , Bruinooge S , et al . Barriers to patient enrollment in therapeutic clinical trials for cancer a landscape report barriers to patient enrollment in therapeutic clinical trials for Cancer- a landscape report project Steering Committee members, 2018. Available: https:\/\/www.acscan.org\/policy-resources\/clinical-trial-barriers [Accessed 21 Dec 2021]."},{"key":"2025121407011732000_12.10.e064458.8","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-10","article-title":"Factors influencing recruitment to research: qualitative study of the experiences and perceptions of research teams","volume":"14","author":"Newington","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2025121407011732000_12.10.e064458.9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/EDBK_156686","article-title":"The role of clinical trial participation in cancer research: barriers, evidence, and strategies","volume":"35","author":"Unger","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025121407011732000_12.10.e064458.10","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2016.0064"},{"key":"2025121407011732000_12.10.e064458.11","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv324","article-title":"Predicting Low Accrual in the National Cancer Institute\u2019s Cooperative Group Clinical Trials","volume":"108","author":"Bennette","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2025121407011732000_12.10.e064458.12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1633"},{"key":"2025121407011732000_12.10.e064458.13","unstructured":"FDA . Hematology\/Oncology (Cancer) Approvals & Safety Notifications. Available: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/hematologyoncology-cancer-approvals-safety-notifications [Accessed 06 Jun 2021]."},{"key":"2025121407011732000_12.10.e064458.14","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/annonc\/mdx793","article-title":"Crossover is not associated with faster trial accrual","volume":"29","author":"Chen","year":"2018","journal-title":"Ann Oncol"},{"key":"2025121407011732000_12.10.e064458.15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cncr.33934","article-title":"Trends in drug revenue among major pharmaceutical companies: a 2010-2019 cohort study","volume":"128","author":"Meyers","year":"2022","journal-title":"Cancer"},{"key":"2025121407011732000_12.10.e064458.16","unstructured":"National Cancer Institute . Surveillance, epidemiology, and end results program. Available: https:\/\/seer.cancer.gov\/ [Accessed 04 May 2021]."},{"key":"2025121407011732000_12.10.e064458.17","doi-asserted-by":"crossref","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2025121407011732000_12.10.e064458.18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/JU.0000000000000294","article-title":"Variation in Accrual and Race\/Ethnicity reporting in urological and Nonurological related cancer trials","volume":"202","author":"Paul","year":"2019","journal-title":"J Urol"},{"key":"2025121407011732000_12.10.e064458.19","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamainternmed.2019.0583","article-title":"An overview of cancer drugs Approved by the US food and drug administration based on the surrogate end point of response rate","volume":"179","author":"Chen","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2025121407011732000_12.10.e064458.20","unstructured":"Taylor P . Top 15 best-selling cancer drugs in 2022. In: FiercePharma, 2017: 1\u201316. http:\/\/www.fiercepharma.com\/special-report\/herceptin-2"},{"key":"2025121407011732000_12.10.e064458.21","unstructured":"Keytruda (pembrolizumab) FDA Approval History - Drugs.com. Available: https:\/\/www.drugs.com\/history\/keytruda.html [Accessed 26 Dec 2021]."},{"key":"2025121407011732000_12.10.e064458.22","unstructured":"Opinion | Faltering Cancer Trials - The New York Times. Available: https:\/\/www.nytimes.com\/2010\/04\/25\/opinion\/25sun1.html [Accessed 21 Dec 2021]."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-064458","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:01:30Z","timestamp":1765724490000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-064458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":22,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,7]]},"published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1136\/bmjopen-2022-064458"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-064458","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}